AR is recruited to a negative androgen response element on the promoter of SRD5A3 and the different expression levels of 5α-reductase isoenzymes affect patient response to 5α-reductase inhibitors in prostate cancer [40]. Here, SRD5A3 is linked to prostate cancer.